Treatment(s) already received-Biological therapy-Targeted Therapy Posts on Medivizor
Navigation Menu

Treatment(s) already received-Biological therapy-Targeted Therapy Posts on Medivizor

Heart-related side effects of tyrosine kinase inhibitors in chronic myeloid leukemia

Posted by on Mar 31, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the risk of cardiovascular (heart and blood vessel) side effects in patients with chronic myeloid leukemia who were treated with tyrosine kinase inhibitors. This study concluded that these side effects were more frequent in this group of patients. Some background Cardiovascular events (CVE) have been...

Read More

Symptom burden for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

Posted by on Oct 30, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the symptom burden on patients with chronic phase chronic myeloid leukemia (CP-CML) who were treated with second or third generation tyrosine kinase inhibitors. This study concluded that the side effects of this treatment may affect the quality of life for these patients. Some background Chronic myeloid...

Read More

Evaluating nilotinib as a consolidation therapy for patients with chronic myeloid leukemia

Posted by on Sep 8, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to evaluate the effectiveness of nilotinib as a consolidation therapy for patients with chronic myeloid leukemia who had achieved a major response with imatinib. This study concluded that nilotinib led to safer, deeper responses in these patients. Some background Imatinib (Gleevec) is a tyrosine kinase inhibition (TKI)...

Read More

Evaluating nilotinib and dasatinib in pediatric patients with chronic myeloid leukemia

Posted by on Aug 21, 2018 in Leukemia | 0 comments

In a nutshell This study evaluated the effectiveness and safety of second-generation tyrosine kinase (TK) inhibitors after imatinib (Gleevec) therapy in children and adolescents with chronic myeloid leukemia (CML). The authors concluded that second-generation TK inhibitors may be a viable first-line treatment option for these patients. Some background...

Read More

Evaluating vascular safety of TK inhibitors in patients with chronic myeloid leukemia

Posted by on Aug 18, 2018 in Leukemia | 0 comments

In a nutshell This study investigated the vascular (blood vessels) side effects associated with tyrosine kinase inhibitors in patients with chronic myeloid leukemia (CML). This study concluded that patients treated with nilotinib (Tasigna) experienced more vascular side effects. Some background Tyrosine kinase (TK) inhibitors are the standard therapy...

Read More

The effect of other conditions on ibrutinib treatment of CLL

Posted by on Jun 26, 2018 in Leukemia | 0 comments

In a nutshell The study looked at the impact of other medical conditions (comorbidities) on the effectiveness of ibrutinib (Imbruvica) in the treatment of chronic lymphocytic leukemia (CLL). The study concluded that having a number of other conditions was associated with a poorer prognosis in CLL patients treated with ibrutinib. Some background...

Read More

Can tyrosine kinase inhibitors influence survival rates in chronic phase chronic myeloid leukemia?

Posted by on Jun 8, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the side effects of tyrosine kinase inhibitors and their impact on outcomes in chronic-phase chronic myeloid leukemia patients. This study concluded that severe side effects from tyrosine kinase inhibitors can cause decreased survival rates in these patients. Some background Tyrosine kinase inhibitors...

Read More

Can chronic myeloid leukemia patients discontinue dasatinib after a year of deep molecular response?

Posted by on May 12, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to investigate if dasatinib could be successfully discontinued in chronic myeloid leukemia patients who were receiving it as a second line treatment after a year of deep molecular response. This study concluded that it was possible to discontinue dasatinib use in this group of patients. Some background Imatinib...

Read More

Switching from imatinib to dasatinib for chronic phase chronic myelogenous leukemia patients

Posted by on Apr 18, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to investigate if side effects of imatinib (Gleevec) treatment in chronic phase chronic myelogenous leukemia would improve if patients were switched to dasatinib (Sprycel) treatment. This study concluded that these patients experience improvements in side effects and quality of life once they switch treatment. Some...

Read More

How safe and effective is ponatinib for chronic phase chronic myeloid leukemia patients?

Posted by on Apr 18, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the effectiveness and safety of ponatinib (Iclusig) for patients with chronic phase chronic myelogenous leukemia. This study concluded that ponatinib is safe and effective in this group of patients. Some background The Philadelphia chromosome (BCR-ABL1) is found in almost all patients with chronic...

Read More

Treatment options for chronic myeloid leukemia patients with failed imatinib treatment

Posted by on Apr 18, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of dasatinib (Sprycel) and nilotinib (Tasigna) in chronic phase chronic myeloid leukemia patients with failed imatinib (Gleevec) treatment. This study concluded that dasatinib and nilotinib were safe and effective in this group of patients. Some background Chronic...

Read More